New model could predict lymphoma progression two years early
NCT ID NCT03436602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of disease progression two years after their first treatment. Researchers will combine clinical information with molecular data from 370 patients to build and test this model. The goal is to better identify which patients are likely to do well and which may need closer monitoring or different treatment approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcispedale Santa Maria Nuova, AUSL IRCSS, Hematology Department
Reggio Emilia, RE, 42123, Italy
-
Azienda Ospedaliera Universitaria Maggiore della Carità
Novara, 28100, Italy
-
Institute of Oncology Research
Bellinzona, Canton Ticino, 6500, Switzerland
-
Institute of Pathology
Locarno, Canton Ticino, Switzerland